Clinical

Dataset Information

0

Phase II study of Bevacizumab with SOX (S-1 plus L-OHP) as second-line therapy in metastatic colorectal cancer


ABSTRACT: Interventions: Bevacizumab with SOX (S-1 plus L-OHP) repeat every 21 days until discontinuance criteria. Primary outcome(s): Response Rate Study Design: Single arm Non-randomized

DISEASE(S): Metastatic Colorectal Cancer

PROVIDER: 2620638 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| PRJEB22589 | ENA
2011-11-01 | E-GEOD-33024 | biostudies-arrayexpress
2021-11-12 | E-MTAB-10805 | biostudies-arrayexpress
2021-11-12 | E-MTAB-10806 | biostudies-arrayexpress
| 2627046 | ecrin-mdr-crc
| 2622829 | ecrin-mdr-crc
| 2622332 | ecrin-mdr-crc
2009-12-31 | E-GEOD-18830 | biostudies-arrayexpress
2009-12-31 | GSE18830 | GEO
| 2622133 | ecrin-mdr-crc